前列腺特异性抗原、前列腺健康指数与前列腺癌临床病理特征的相关性分析

摘要/Abstract

摘要： 目的探讨前列腺特异性抗原（PSA）、前列腺健康指数（PHI）与前列腺癌临床病理特征的相关性。方法选取2020年8月—2023年8月乐山市市中区人民医院收治的80例经活检病理诊断确诊为前列腺癌的患者作为研究对象,将其分为恶性组,另选取同期在乐山市市中区人民医院活检病理诊断确诊为良性前列腺增生的80例患者作为良性组。分别采取两组患者的肿瘤组织进行免疫组化检测,检测PSA表达,并比较其阳性率,并计算PHI,比较其PHI水平。随后分析不同临床病理特征前列腺癌患者的PSA阳性率与PHI水平,并应用logistic回归分析法分析PSA、PHI与前列腺癌临床病理特征的关系。结果两组受检者PSA、PHI表达水平比较,差异有统计学意义（P<0.05）。恶性组患者PSA阳性率和PHI表达水平明显高于良性组,差异有统计学意义（P<0.05）;80例前列腺癌患者中,不同年龄、T分期PHI水平比较,差异无统计学意义（P>0.05）;不同年龄PSA阳性率比较,差异无统计学意义（P>0.05）。不同淋巴结转移、远处转移、Gleason评分、危险分级患者PHI水平比较,差异有统计学意义（P<0.05）;不同T分期、淋巴结转移、远处转移、Gleason评分、危险分级患者PSA阳性率比较,差异有统计学意义（P<0.05）。多因素logistic分析结果表明：T分期、淋巴结转移、远处转移、Gleason评分为PSA阳性表达的危险因素（95%CI：1.259~2.457、1.364~3.475、1.176~4.010、1.036~2.745;P=0.030、0.023、0.016、0.005）。淋巴结转移、远处转移、Gleason评分、危险分级为PHI水平升高的危险因素（95%CI：1.362~3.783、0.826~2.926、1.221~3.525、0.315~1.425;P=0.042、0.031、0.026、0.011）。结论前列腺癌患者的PSA阳性率、PHI表达水平明显升高,且T分期、淋巴结转移、远处转移、Gleason评分为PSA阳性表达的危险因素,淋巴结转移、远处转移、Gleason评分、危险分级为PHI水平升高的危险因素。

关键词: 前列腺特异性抗原, 前列腺健康指数, 前列腺癌, 临床病理特征, 相关性

Abstract: Objective To investigate the correlation between prostate specific antigen (PSA),prostate health index (PHI) and clinicopathological features of prostate cancer. Methods A total of 80 patients with prostate cancer diagnosed by biopsy pathology in People's Hospital of Shizhong District, Leshan City from August 2020 to August 2023 were selected as the research object and divided into malignant group, and another 80 patients diagnosed with benign prostatic hyperplasia through biopsy pathology in our hospital during the same period were selected as the benign group. The tumor tissues of the two groups were detected by immunohistochemistry, the expression of prostate specific antigen (PSA) was detected, and the positive rate was compared. The prostate health index (PHI) was calculated, and the phi level was compared. Then the positive rate of PSA and phi level in patients with prostate cancer with different clinicopathological characteristics were analyzed, and the relationship between PSA, phi and clinicopathological characteristics of prostate cancer was analyzed by logistic regression analysis. Results there were significant differences in the expression levels of PSA and phi among the two groups. The positive rate of PSA and the expression level of pHi in the malignant group were significantly higher than those in the benign group (P<0.05); In 80 patients with prostate cancer, there was no significant difference in pHi level between different ages and T stages, and there was no significant difference in PSA positive rate between different ages (P>0.05). There was significant difference in pHi level between patients with different lymph node metastasis, distant metastasis, Gleason score and risk classification, and there was no significant difference in PSA positive rate between patients with different T stages, lymph node metastasis, distant metastasis, Gleason score and risk classification (P<0.05); Multivariate logistic analysis showed that T stage, lymph node metastasis, distant metastasis and Gleason score were risk factors for PSA positive expression （95%CI：1.259~2.457、1.364~3.475、1.176~4.010、1.036~2.745;P=0.030、0.023、0.016、0.005）, as shown in Table 3. Lymph node metastasis, distant metastasis, Gleason score and risk classification were the risk factors for the increase of phi level （95%CI：1.362~3.783、0.826~2.926、1.221~3.525、0.315~1.425;P=0.042、0.031、0.026、0.011）. Conclusion The PSA positive rate and PHI expression level of prostate cancer patients are significantly increased, and T stage, lymph node metastasis, distant metastasis, and Gleason score are risk factors for PSA positive expression. Lymph node metastasis, distant metastasis, Gleason score, and risk grade are risk factors for increased PHI level.

Key words: prostate specific antigen, prostate health index, prostate cancer, clinicopathological features, relativity

中图分类号:

R737.25

刘聪, 周文杰, 魏凡杰, 毛伟. 前列腺特异性抗原、前列腺健康指数与前列腺癌临床病理特征的相关性分析[J]. 中华养生保健, 2024, 42(9): 52-55.

LIU Cong, ZHOU Wen-jie, WEI Fan-jie, MAO Wei. Correlation Analysis of Prostate Specific Antigen, Prostate Health Index and Clinical Pathological Characteristics of Prostate Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(9): 52-55.

参考文献

[1] 邹博,龙衍,杨智明,等.湖南地区前列腺癌流行病学及临床病理特征分析[J].中华男科学杂志,2022,28(9):786-791.
[2] 邱海波,曹素梅,徐瑞华.基于2020年全球流行病学数据分析中国癌症发病率,死亡率和负担的时间趋势及与美国和英国数据的比较[J].癌症,2022,41(4):165-177.
[3] 张伟,侯惠民,王淼,等.老年人移行区前列腺癌的临床病理学特征[J].中华老年医学杂志,2021,40(3):323-328.
[4] 骆万超,温红,罗欢嘉,等.经直肠超声测量前列腺体积对游离前列腺特异性抗原密度预测前列腺癌的临床意义[J].现代泌尿外科杂志,2023,28(7):623-626.
[5] 谭智勇,付什,左桀明,等.前列腺健康指数在前列腺癌诊疗中的研究进展[J].中华泌尿外科杂志,2023,44(3):234-236.
[6] 莫利才,蒋武斌,汪佳佳,等.前列腺健康指数密度对PI-RADS v2评分3分中高危前列腺癌的预测价值[J].浙江医学,2023,45(6):590-593,598,后插2.
[7] 《临床泌尿外科杂志》编辑部.欧洲泌尿学会更新前列腺癌诊疗指南[J].临床泌尿外科杂志,2006,21(5):399-400.
[8] 曾浩,魏强,石明,等.前列腺特异性抗原表达与前列腺癌组织学分级的相关性[J].实用癌症杂志,2004,19(1):33-35.
[9] 周晓蝶,王建军,徐向军,等.偶发性前列腺癌的临床病理学研究[J].中华男科学杂志,2021,27(2):145-149.
[10] 付书凡,杜新雨,廖栩鹤,等.前列腺特异性膜抗原显像用于前列腺癌研究进展[J].中国医学影像技术,2023,39(3):453-457.
[11] 郝伟玉,韩颖,武峰美,等.代谢综合征对前列腺特异性抗原的影响分析[J].现代泌尿生殖肿瘤杂志,2023,15(3):162-165,172.
[12] 钱宇航,陈浩杰(综述),虞永江(审校).前列腺健康指数的发现与应用[J].国际泌尿系统杂志,2022,42(6):1134-1136.
[13] 路惠茹,梁亮,谢宏俊,等.前列腺特异性抗原同源异构体2及其衍生指标对PSA 4~20 ng/mL患者前列腺癌的预测价值[J].现代泌尿外科杂志,2023,28(4):347-350,358.
[14] 仁赵玲,马润,胡莹,等.前2肽前列腺特异性抗原与前列腺健康指数在前列腺癌诊断中的应用价值[J].中国医刊,2022,57(4):416-420.
[15] 范博. 转移性前列腺癌患者PSA动力学在不同治疗方案中与预后关系的研究进展[J].国际泌尿系统杂志,2022,42(6):1130-1133.
[16] 张鹏,李鑫钊,梁清,等.血浆纤维蛋白原、前列腺特异性抗原密度与前列腺癌骨转移关系研究[J].中国医药导报,2023,20(17):111-114.